Rac inhibitors

A compound of formula I:

• or a pharmaceutically acceptable salt thereof, wherein
• Z is selected from halogen and C1-4 alkyl wherein said C1-4 alkyl is optionally substituted with one or more halogen atoms;
• R1, R2, and R3 are independently selected from H and halogen;
• X is —S—;
• A is C2-7 alkylene wherein one or more of the methylene groups is optionally replaced with O, N(Rb), C(O), or phenylene;
• B is selected from the group:
• Linker is selected from a bond, —C(O)—, —CH2—N(Rc)—, —CH2—N(Rd)—C(O)—, and C1-2 alkylene wherein said C1-2 alkylene is optionally substituted with OH;
• D is selected from:
• (i) a 4-7 membered ring optionally containing 1 or 2 heteroatoms independently selected from N and O;
• wherein said ring optionally contains a C═O;
• and wherein said ring is optionally substituted with one or more groups selected from halogen, OH, C1-4 alkoxy, C1-4 alkyl optionally substituted with one or more halogen atoms, C(O)—Re, phenyl optionally substituted with C1-4 alkoxy, and a 5 or 6 membered ring containing 1 or 2 heteroatoms independently selected from N and O;
• (ii) —N(Rf)(Rg);
• and
• (iii) —C(O)—O—C1-4 alkyl;
• Rb is C1-4 alkyl;
• Rc and Rd are independently selected from H and C1-4 alkyl,
• Re is selected from C1-4 alkyl and a 5- or 6-membered ring optionally containing 1 or 2 heteroatoms independently selected from N and O;
• Rf is selected from H, C1-4 alkyl, C(O)—C1-4 alkyl, and C(O)—O—C1-4 alkyl;
• and
• Rg is selected from C1-4 alkyl, C1-4 alkylene-O—C1-4 alkyl.